in trials of pegylated ifn monotherapy treatment, there were inadequate numbers of african american subjects to make meaningful conclusions about the role of race in treatment outcomes [40 , 41].
In the registration trials of treatment with pegylated IFN and ribavirin, too few African American subjects were enrolled to make outcome assessments [42 , 43].